Data Showcasing ALZpath's Proprietary pTau217 Antibody at AD/PD™ 2025 Demonstrates High Rate of Reliability and Scalability for Alzheimer's Disease Research and Diagnosis [Yahoo! Finance]
Bio-Techne Corp (TECH)
Last bio-techne corp earnings: 4/30 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.bio-techne.com
Company Research
Source: Yahoo! Finance
CARLSBAD, Calif. April 1, 2025 /PRNewswire/ -- ALZpath, Inc. (ALZpath), a leading developer of diagnostic tools and solutions for Alzheimer's disease and related dementias, announced the inclusion of data from evaluation of blood testing platforms utilizing its proprietary pTau217 antibody in several high-impact presentations at the 2025 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™). The data is based on recent studies conducted by industry leaders, including Beckman Coulter Diagnostics, Bio-Techne, and Neurocode, and will be presented in seven symposia, seven oral presentations, and two poster presentations. Alzheimer's disease and related dementias are expected to impact nearly 153 million people globally by 2050. With the increase of cases and emergence of disease-modifying therapies, there is a greater and more urgent need for widespread, rapid, and accessible diagnostic testing. ALZpath's proprietary pTau217 anti
Show less
Read more
Impact Snapshot
Event Time:
TECH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TECH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TECH alerts
High impacting Bio-Techne Corp news events
Weekly update
A roundup of the hottest topics
TECH
News
- Bio-Techne (NASDAQ:TECH) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Bio-Techne (NASDAQ:TECH) was given a new $72.00 price target on by analysts at Deutsche Bank Aktiengesellschaft.MarketBeat
- Here's Why BioTechne (TECH) Traded Lower in Q3 [Yahoo! Finance]Yahoo! Finance
- Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology [Yahoo! Finance]Yahoo! Finance
- Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial BiologyPR Newswire
TECH
Earnings
- 11/5/25 - Beat
TECH
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/5/25 - Form 4
- 11/5/25 - Form 4
- TECH's page on the SEC website